Related Experiment Video
Updated: Jun 5, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Temozolomide: Expanding its role in brain cancer
M M Mrugala1, J Adair, H-P Kiem
1Department of Neurology and Neurosurgical Surgery, University of Washington, Seattle, Washington 98195, USA. mmrugala@u.washington.edu
Drugs of Today (Barcelona, Spain : 1998)
|January 13, 2011
Summary
Temozolomide, an alkylating agent, improves outcomes for malignant glioma patients. This review covers its development, use in brain cancer therapy, and future applications.
Area of Science:
- Neuro-oncology
- Chemotherapy
- Pharmacology
Background:
- Central nervous system (CNS) malignancies present significant therapeutic challenges due to resistance to conventional treatments.
- Surgery and radiotherapy offer palliative care but rarely achieve curative results for primary and metastatic brain tumors.
- Alkylating agents are a class of chemotherapy drugs that can cross the blood-brain barrier, making them suitable for treating brain cancers.
Purpose of the Study:
- To review the development and application of temozolomide in treating central nervous system malignancies.
- To discuss the efficacy of temozolomide in glioma patients, including elderly populations.
- To explore mechanisms of resistance and future therapeutic directions for temozolomide in brain cancer.
Main Methods:
- Literature review of temozolomide's development and clinical trials.
- Analysis of temozolomide's role in treating newly diagnosed and recurrent malignant glioma.
- Examination of temozolomide's use in combination with radiotherapy and its potential in other CNS cancers.
Main Results:
- Temozolomide, a second-generation alkylating agent, has shown improved outcomes when used alone or with irradiation for malignant glioma.
- The drug has been approved for both newly diagnosed and recurrent malignant glioma.
- Ongoing research is exploring its role in other brain cancers, such as primary CNS lymphoma.
Conclusions:
- Temozolomide represents a significant advancement in the management of malignant glioma.
- Understanding resistance mechanisms is crucial for optimizing temozolomide therapy.
- Further research will define the evolving role of temozolomide in neuro-oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...